Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Center Registration Study on HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer.

NCT06146114 is registered in ClinicalTrials.gov with Qilu Hospital of Shandong University as lead sponsor.

NCT NCT06146114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06146114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Center Registration Study on HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer.
Lead sponsor
Qilu Hospital of Shandong University
Phase
Observational
Overall status
Unknown status
Start date
July 1, 2023
Completion date
December 1, 2024
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2 expression and clinical pathological characteristics in prostate cancer